Glaxo Group Limited v. Genentech, Inc.
2:10-cv-02764
Overview
Parties
Defendant
Counter Claimant
Lonza Biologics Inc. Operating Company
Represented By
4 Attorneys ListedLonza Biologics PLC NPE (Individual / Inventor)
Represented By
4 Attorneys ListedCounter Defendant
Third Party Plaintiff
Court & Judges
Court
District Court, C.D. California (cacd)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360ยฐ RadarMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| ๐บ๐ธ United States | US 6,331,415 Asserted | Asserted Patent | View Official Patent → |
Merck Sharp & Dohme Corp. v. Genentech, Inc. et al.
Merck Sharp & Dohme Corp. v. Genentech, Inc. et al.
Mylan Pharmaceuticals Inc. et al. v. Genentech, Inc. et al.
Genzyme Corporation et al. v. GENENTECH, INC. et al.
GENZYME CORPORATION et al. v. Genentech Inc. et al.
Sanofi-Aventis U.S. LLC et al. v. Genentech, Inc. et al.
Genentech, Inc. v. Immunex Rhode Island Corp.
Genentech, Inc. v. Samsung Bioepis Co., Ltd.
Eli Lilly and Company v. Genentech, Inc.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
| US6331415 |
Filed: โ
Issued: โ
|
Term Verification Pending
Expires: โ
|
Patent Enforceability & Injunction Risk Assessment
Active Threat โ Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.
Standard Statutory Term โ No obviousness-type double patenting truncation noted.
Under 35 U.S.C. ยง 286, damages cannot accrue for infringement prior to 6 years before filing. Standard Maintenance Fee Schedule Tracked (3.5, 7.5, 11.5 Years).
Procedural Motions & Interlocutory Orders
Total Motions
82
Dispositive
58
Granted
14
Denied
0
Pending / Review
67
Motions by Category
Key Dispositive Motions & Rulings